Additionally, patients with AS receiving TNFi or anti-IL-17A therapy in a smaller multicentre study demonstrated significant associations between Functional Assessment of Chronic Illness Therapy – Fatigue and Insomnia Severity Index scores (P < 0.0001 and P = 0.0001, respectively) [89]. This evidence concerns the gene IL17A and insomnia measurement.